🔍 Does AI reduce #clinician workload?

@NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️

💡AI tools need to be developed in comjuction with 🩺🥼🧑‍⚕️ not in silos
#AIinMedicine #LLMs @oncoalert.bsky.social

🚨 Breakthrough therapy for ES-SCLC!

@FDA grants sacituzumab govitecan BTD for ES-SCLC progressing on platinum chemo, based on phase II TROPiCS-03 data:
🔹 ORR: 41.9%
🔹 Disease control: 83.7%
🔹 Clinical benefit: 48.8%

Next step: phase III trials. 🤞 this provides another option

#LCSM #SCLC

Absolutely stunning progress in #lcsm! 🫁
📈 Each month of 2024 has brought incredible advancements—remarkable strides in lung cancer treatment! 💉
✨ Here's another perspective on this impressive journey. Just Ah-mazing! @oncodaily.bsky.social @n8pennell.bsky.social @jackwestmd.bsky.social

Phase I Results AMG 193, PRMT5 inhibitor targeting MTAP-deleted solid tumors: @AnnalsOncology

• 📊 ORR: 21.4% across 8 tumor types (incl. NSCLC, pancreatic & biliary)
• 🛡️ Safety: minimal myelosuppression; nausea & fatigue
• 🎯 MoA: Synthetic lethality in MTAP-deleted cells! @oncoalert.bsky.social

📢 Breaking news in #SCLC treatment!

Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).

This approval marks an important step forward for patients with limited-stage SCLC! 💪

Thrilled to be starting “AI in Health Care: From Strategies to Implementation program” @harvardmed! 🧠💻 Embarking on this to deepen my understanding and applications of AI to revolutionize #medicine and #oncology!
Excited to apply these insights to patient care! 🌟 #AIInMedicine #StudentforLife

Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer - @ClinicalLung
◾️ Median OOP cost of $98 (IQR: $43.8-$306.5)
◾️Biomarker testing total OOP cost of all services in 6 mths of diagnosis: $3560.2 compared to $1979.6 for those who did not! bit.ly/4hUTqaa

#FDAOncology approves a biparatopic, Zanidatamab- targeting HER2 for #BTCs
Based on HERIZON-BTC-01!
➡️ORR: 41.3%, mDOR=14.9 mths
➡️ Approval for IHC 3+, where TDX-d also has agnostic approval
➡️18% Gr3 TRAEs, diarrhea
#Oncosky @oncoalert.bsky.social @viveksubbiah.bsky.social

Exciting times in #NSCLC with multiple immunotherapy approvals in early stage! 🎉

But navigating these options can be complex. Glad to partner with @OncLearnNetwork to create patient case-based education, bridging the gap between advancements and real-world application.
bit.ly/498ffPB